HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on Acrivon Therapeutics (NASDAQ:ACRV) and maintained a $20 price target.
September 06, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acrivon Therapeutics' stock may see positive movement as HC Wainwright & Co. has reiterated a 'Buy' rating and maintained a $20 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $20 by HC Wainwright & Co. indicates their continued confidence in Acrivon Therapeutics, which could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100